Top Links
Journal of Antibiotics Research
ISSN: 2574-5980
Analysis of Antibody by Real-Valued Special Functions
Copyright: © 2018 Zhao B. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at Pubmed, Google Scholar
Background: Along with the rapid development of genetic engineering technology and antibody engineering technology, humanized monoclonal antibody has been rapidly developed and gradually replaces the rat sourced monoclonal antibody. In this paper, we establish two new logarithmically completely monotonic functions involving the real-valued special functions according to two preferred interaction geometries, necessary and sufficient conditions are presented for one of them to be logarithmically completely monotonic. As a consequence, a sharp inequality involving the real-valued special functions is deduced to solve the problems of genetically engineered antibody.
Keywords: Real-valued Special Functions; Genetically Engineered Antibody; Logarithmically Completely Monotonic; Inequality; Psi function
Antibodies have been proven to be indispensable tools for biomedical applications. Different engineered antibodies have been developed for various purposes according to the amino acid sequence and/or spatial structure of protein (Figure 1). At present, it is still difficult to predict the optimal structure of antibodies. Topology knowledge can be important in antibody application as well as transformation. Theoretically, we can obtain desired antibodies by using protein/gene engineering technology. For instance, we can transform the complementarity determining region (CDR) to promote the affinity of the antibody to antigen. Similarly, we could also transform any domain of antibody to make it bind with any desired target. Under this vision, topology is a powerful tool to predict the structure of protein and it will serve to antibody engineering. Our present work tries to explain, and predict, if possible, the change of structure, size and function of antibodies as well as their fragments from a topological perspective.
For the classical Euler’s gamma function
and psi (digamma) function
are defined by

respectively. The derivatives for
are known as polygamma functions. For
[1], the following series representations are established :
where denotes the Euler’s constant.
We next recall that a function f is said to be completely monotonic on an interval I , if f has derivatives of all orders on I which alternate successively in sign, that is,

for all and for all
. If inequality (1.5) is strict for all
and all
, then f is said to be strictly completely monotonic [2-5].
The classical Bernstein–Widder theorem [6, p. 160, Theorem 12a] states that a function f is completely monotonic on if and only if it is a Laplace transform of some nonnegative measure
, that is,

where is non-decreasing and the integral converges for x >0 .
We recall also that a positive function f is said to be logarithmically completely monotonic on an interval I if f has derivatives of all orders on I and

for all and for all
. If inequality (1.7) is strict for all
and all
, then f is said to be strictly logarithmically completely monotonic [7-9].
The antibody structure will be changed when it binds certain targets (Figure 2a), i.e.: antigen, receptor. How to describe the changes in the view of topology? The following cases will explain it in detail.
It was proved explicitly in and other articles that a logarithmically completely monotonic function must be completely monotonic [8]. In [10], G. D. Anderson et al. proved that the function

is strictly decreasing and strictly convex on , with two limits

From (1.9) and the monotonicity of g(x), then the double inequalities

holds for all x >0.
In [11, Theorem 1], by using the well-known Binet’s formula, H. Alzer generalized the monotonicity and convexity of g(x), that is, the function

is strictly completely monotonic on if and only if
.
In [12], D. Kershaw and A. Laforgia proved that the function is decreasing on
and
is increasing on
. These are equivalent to the function
being increasing and
being decreasing on
, respectively.
In [13,Theorem 5], F. Qi and Ch.-p. Chen generalized these functions. They obtained the fact that for all x>0 the function is strictly increasing for
and strictly decreasing for
, respectively.
After the papain digestion, the remained antibody functional part (usually the Fab domain), will be smaller and the structure is also changed (Figure 1b). These changes can be revealed vividly using topology. Recently [14,Theorem 1], F. Qi, C.-F Wei and B.-N Guo established another excellent result, which states that for given and
, let

The function (1.12) is logarithmically completely monotonic with respect to if and only if
; and if
, the reciprocal of the function (1.12) is logarithmically completely monotonic with respect to
Antibodies occur spontaneously gathering and forming dimer, polymer, which will influence their functions (Figure 2b). In antibody engineering practice, it urgently needs some measures to overcome this difficulty. From topology perspective, we could understand this issue as follow.
Stimulated by the above results, we put forward the function as follows: for given and real number
, let the function
be defined by

Our first result is contained in the following theorem.
Theorem 1: For the function (1.13), then the following statements are true:
1) for any given , the function (1.13) is strictly logarithmically completely monotonic with respect to
if and only if
;
(2)for any given 0;
(3) for any given y>0, the reciprocal of the function (1.13) is strictly logarithmically completely monotonic with respect to if and only if
.
Our second result is presented in the following theorem.
Theorem 2: For any given , let the function
be defined on
by

where denotes the Euler’s constant, then the function (1.14) is strictly logarithmically completely monotonic with respect to x on
.
The following corollary can be derived from Theorems 2 immediately.
Corollary 1: For any given , the inequality

holds for all x>0.
In order to prove our main results, we need the following lemmas.
It is well known that Bernoulli polynomials and Euler polynomials
are defined by
Respectively [15]. The Bernoulli numbers Bn are denoted by Bn= Bn(0), while the Euler numbers En are defined by En = 2nEn(1/2).
In [16], the following summation formula is given:

for any nonnegative integer k, which implies

In particular, it is known that for all



And the first few nonzero values are

The Bernoulli and Euler numbers and polynomials are generalized ([18-21]).
(see [17, p.804, Chapter23]).
Lemma 1: For real number x > 0 and natural number m[22,23], then





Remark 1: only depend on natural number m.
Lemma 2: For real number x > 0 and natural number ([24, p. 107, Lemma 3]),
we have

Lemma 3: (see [1,17]) For real number x > 0 and natural number , we have

Lemma 4: Let the sequence of functions for for
be defined on
by

the series is differentiable on
, that is,

Proof: It is obvious that , therefore
converges at x=0. In order to prove (2.16), we need only to show that,
the inner closed uniform convergence of the series on
. From (2.15), we have

For any interval


for all . It is easy to check that the series
converges, which and
Weierstrass M-test implies that the series is inner closed uniformly convergent on
.
Hence the series is differentiable on
and the identity (2.17) holds for
.
The lemma is proved.
Lemma 5: For and real number b, let the function
be defined by

If


for all ,

: Taking the logarithm of yields

and differentiating


For given integer , we get

and, by the identities (2.13) and (2.14), (2.23) can be written as

Let and
. It is easy to check that

therefore q(t) is strictly increasing on , and then
.
The following two cases will complete the proof of Lemma 5.
Case 1: If , then since q(t) > 0 for t > 0, we have

which implies , and then p(t) > 0 for all t > 0.
Case 2: If , then we get


therefore p(t) is strictly increasing on


From (2.24), we know that the inequality (2.20) holds for and integer .
The lemma is proved.
Proof of Theorem 1: For and natural number n, taking the logarithmically
differential into consideration yields

where and
stand for
and
respectively.
Furthermore, differentiating directly gives

Making use of (2.11) and (2.13) shows that for all




holds for all


For any fixed , let u(t) and v(t) be defined on
by


respectively.
Differentiating u(t) and v(t) directly, we obtain


Therefore, for given we have


From (3.6) and (3.7), we conclude that for all t > 0 we obtain


From (3.3) and (3.8)-(3.9), it is easy to see that

for all


On the one hand, if , then the inequalities (3.10) can be equivalently
changed into

and

for

From (3.1), then simple computation shows that

for all



and

for all

Therefore, (3.14) and (3.15) imply

for all

Hence, if either for given 0 < y < 1 or for given
, the function (1.13) is strictly logarithmically completely monotonic with respect to x on
, and if
for given y > 0, so is the reciprocal of the function (1.13).
On the other hand, if for any given y > 0, then (3.10) implies

for all

In view of (3.13), we can conclude that

for




The amino acid of antibody/protein possesses different preferences. Thus we can conduct site-directed mutation to promote the affinity and/or hydrophilic with the prediction of topology. For example, bovine antibodies have an unusual structure comprising a β-strand ‘stalk’ domain and a disulphide-bonded ‘knob’ domain in CDR3 (Figure 3). Attempts have been made to utilize such amino acid preference for antibody drug development.
Consequently, the function (1.13) is the same logarithmically completely monotonicity on (-y, 0) as on , that is, if either
for given 0 < y < 1 or
for given
, the function (1.13) is strictly logarithmically completely monotonic with respect to x on (-y, 0), and if
for given y > 0, so is the reciprocal of the function (1.13).
Conversely, we assume that the reciprocal of the function (1.13) is strictly logarithmically completely monotonic on for any given y > 0. Then we have for any given y > 0 and all x > 0


By L’Hˆospital’s rule, we have

for any given y > 0. By virtue of (3.20) and (3.21), we conclude that the necessary condition for the reciprocal of the function (1.13) to be strictly logarithmically completely monotonic is

If the function (1.13) is logarithmically completely monotonic on
for any given y > 0, then the inequality (3.19) and (3.20) are reversed for any given y > 0 and all x > 0.
By utilizing (2.7) and (2.8), it is easy to see that
for any given y > 0. In fact, it is not difficult to show that the necessary condition for the function (1.13) to be strictly logarithmically completely monotonic is

The proof of Theorem 1 is completed.
Proof of Theorem 2: Taking the logarithm of gives

Let


then

In view of Lemma 4, straightforward calculation gives

By virtue of (1.2), the identity (3.27) is equivalent to

By Lemma 5, we know that is strictly increasing on
, which and (1.10) imply the limit of
equals 1 as
, therefore
holds for all x > 0.
We know that g(x) is strictly completely monotonic on , where g(x) is defined by (1.8), hence for given integer
, the inequality
holds for all x > 0.
And then by using inequality (1.9) and (1.10), we getReferences

for all x > 0.
From (3.29) and (3.31), we conclude that

for all x > 0. Utilizing Lemma 5 and (3.30), for given integer


for all x > 0.
Theorem 2 follows from (3.32) and (3.33).
Thus the proof of Theorem 2 is completed.
In conclusion, we establish two new logarithmically completely monotonic functions involving the real-valued special functions according to two preferred interaction geometries, and a sharp inequality involving the real-valued special functions is deduced to solve the problems of genetically engineering antibodies. It is necessary to address, many other aspects (such as thermal condition, alkalinity or acidity, adhesion of antibodies) are also playing key roles in antibodies functioning, which could be also understood from bio-mathematical perspective, and such knowledge will be in return useful for biomedical application of antibodies as well as proteins [25-30].
We would like to express my gratitude to all those who helped us during the writing of this article.
Figure 1: Different antibody formats. a: different antibody or engineered antibodies; b: different shape of antibody |
Figure 2: Model of pH-dependent conformational change of FcRY and structures for the FcRY monomer and dimer. a: FcRY has an extended conformation at pH 8 (s*= 7.2 S) with no predicted interaction between the CysR-FNII domains and the CTLDs. At pH 6 the CysR-FNII region folds back and binds to the CTLDs, resulting in a more compact conformation (s*= 7.9 S) that is able to bind IgY. b: Likely orientations of FcRY and FcRY–IgY on a membrane. The two FcRY monomers on the Right are shown in an orientation that would allow formation of a 2:1 FcRY–IgY complex |
Figure 3: Unique Structural Domain in Bovine IgG antibodies and application |